Dr. Jeff's and Dr. Tanya's Blog

The best patient guide on clinical trials for Social Phobia (Social Anxiety Disorder)

Social Phobia (Social Anxiety Disorder)

Featured Studies

Featured studies include only those currently recruiting participants. They are listed according to the date they were added to the ClinicalTrials.gov registry, with the most recent studies appearing first.

• Effect of D-Cycloserine Plus Cognitive Behavioral Therapy on People With Social Phobia.
  Interventional study. This study will assess the effectiveness of D-cycloserine combined with cognitive-behavior therapy in treating people with social anxiety disorder. Ages 18 and over. Location in Boston, MA.

• Effect of Behavior Therapy on Responses to Social Stimuli in People With Social Phobia.
  Interventional study. This study will evaluate the effect of cognitive behavioral therapy on the brain during emotional and behavioral responses to social stimuli in people with social phobia. Ages 21-55. Location in Stanford, CA.

• Improving Treatment Outcomes in Pharmacotherapy of Generalized Social Anxiety Disorder.
  Interventional study. This study will compare the effectiveness of either adding clonazepam or placebo to standard treatment or switching to venlafaxine in treating generalized social anxiety disorder in individuals who have not responded to treatment with sertraline. Ages 18 and over. Locations in La Jolla, CA; Boston, MA; Hamilton, ON.

Source: National Institute of Mental Health

Dr. Jeffrey Speller
Dr. Tanya Korkosz
Psychopharmacology Associates of New England
www.psychopharmassociates.com

The best patient guide on clinical trials for Schizophrenia

Schizophrenia

Featured Studies

Featured studies include only those currently recruiting participants. They are listed according to the date they were added to the ClinicalTrials.gov registry, with the most recent studies appearing first.

• Effectiveness of Neuroadaptive Cognitive Training in Adolescents at Risk for Psychosis.
  Interventional study. This study will evaluate the effectiveness of intensive computerized cognitive training in preventing the onset of psychotic disorder and improving adaptive functioning in adolescents at high risk of schizophrenia. Ages 16-25. Locations in Davis, CA; San Francisco, CA.

• Effectiveness of Vitamin Supplementation in Treating People With Residual Symptoms of Schizophrenia.
  Interventional study. This study will evaluate the effectiveness of folate and B12 supplementation in reducing negative symptoms in people with schizophrenia. Ages 18-68. Location in Boston, MA.

• Social Cognition and Interaction Training for Improving Social Functioning in People With Schizophrenia.
  Interventional study. This study will determine the effectiveness of social cognition and interaction training, a manual-based group therapy program, in helping people with schizophrenia improve their social cognition and social functioning. Ages 18-65. Location in Chapel Hill, NC.

• Effects of Motivating People With Schizophrenia to Exercise.
  Interventional study. This study will evaluate the impact of motivational guidance to exercise on people with schizophrenia, based on their participation in a walking program. Ages 22 and over. Location in Knoxville, TN.

• The Effects of Atomoxetine on Cognition and Brain Function Based on COMT Genotype.
  Interventional study. This study will evaluate whether Atomoxetine improves cognition in healthy volunteers as well as patients with schizophrenia. Ages 18-45. Location in Bethesda, MD.

• A Self-Management Program for Adults With Both Schizophrenia and a Co-Occurring Medical Condition.
  Interventional study. This study will develop and evaluate the effectiveness of a self-management program for adults living with both schizophrenia and a co-occurring medical condition. Ages 18-64. Location in Baltimore, MD.

• The Use of Galantamine and CDP-Choline to Treat Adults With Schizophrenia.
  Interventional study. This study will evaluate the effectiveness of galantamine and CDP-choline in improving symptoms associated with schizophrenia. Ages 18-70. Location in Washington, DC.

• Effectiveness of Tropisetron Plus Risperidone for Improving Cognitive and Perceptual Disturbances in Schizophrenia.
  Interventional study. This study will determine the effectiveness of tropisetron plus risperidone in improving cognitive and perceptual disturbances and symptoms in Chinese people with schizophrenia. Ages 18-64. Locations in Beijing, China; Houston, TX.

• Comparison of Video Consent Versus Routine Consent for Participation in Research Studies.
  Interventional study. The purpose of this study is to examine a novel technique for improving the informed consent process for participation in research by the older psychiatric population. Ages 40 and over. Location in San Diego, CA.

• Comparison of Antipsychotics for Metabolic Problems in the Treatment of People With Schizophrenia or Schizoaffective Disorder.
  Interventional study. The study will compare the effectiveness of antipsychotic medications for patients with schizophrenia or schizoaffective disorder for whom a medication change may be indicated because of an increased risk of cardiovascular disease. Ages 18-65. Locations in Colton, CA; Orange, CA; Palo Alto, CA; San Diego, CA; Farmington, CT; New Haven, CT; Boca Raton, FL; Miami, FL; Atlanta, GA; Augusta, GA; Iowa City, IA; Wichita, KS; Shreveport, LA; Boston, MA; Fall River, MA; Worcester, MA; Glen Burnie, MD; Detroit, MI; Minneapolis, MN; St. Louis, MO; Butner, NC; Chapel Hill, NC; Charlotte, NC; Albuquerque, NM; New York, NY; Rochester, NY; Cincinnati, OH; Philadelphia, PA; Conroe, TX; Dallas, TX; Houston, TX; San Antonio, TX; Tacoma, WA; Milwaukee, WI.

• Improving Adherence to Oral Antipsychotic Medications in People With Schizophrenia.
  Interventional study. This study will determine the comparative effectiveness of two systems designed to improve medication adherence in people with schizophrenia. Ages 18-60. Location in San Antonio, TX.

• Improving Medication Adherence Among People With Schizophrenia Through the Use of 2-Way Pagers.
  Interventional study. This study will determine whether using a pager improves medication adherence in people with schizophrenia. Ages 18 and over. Location in Glen Oaks, NY.

• Attention Shaping Procedures for Improving Psychosocial Skills Among Adults With Schizophrenia.
  Interventional study. This study will evaluate the effectiveness of attention shaping procedures in improving attentiveness and learning abilities in people undergoing psychosocial skills training treatment for schizophrenia. Ages 18-55. Locations in Monmouth Junction, NJ; New Brunswick, NJ.

• Measuring Smoking Behavior in People With Schizophrenia and Bipolar Disorder.
  Evaluation study. This study will evaluate the differences in smoking behavior, nicotine intake, and nicotine boost among people with schizophrenia, bipolar disorder, or no mental illness. Ages 18-75. Location in New Brunswick, NJ.

• Culturally Based Family Therapy for Improving Treatment Outcome for People With Schizophrenia.
  Interventional study. This study will evaluate the effectiveness of a culturally based family therapy intervention in improving treatment outcome in people with schizophrenia. Ages 13 and over. Location in Coral Gables, FL.

• Guanfacine for Improving Cognitive Symptoms in People With Schizotypal Personality Disorder.
  Interventional study. This study will determine the effectiveness of guanfacine in improving symptoms of schizotypal personality disorder. Ages 18-60. Location in New York, NY.

• Effectiveness of Aripiprazole for Improving Side Effects of Clozapine in the Treatment of People With Schizophrenia.
  Interventional study. This study will evaluate the effects of combination treatment with aripiprazole and clozapine on insulin resistance, blood fat levels, and weight gain in people with schizophrenia. Ages 18-65. Location in Boston, MA.

• Effectiveness of a Lifestyle Intervention for Increasing Physical Activity in Adults With Schizophrenia.
  Interventional study. This study will evaluate the effectiveness of a lifestyle intervention in increasing physical activity and reducing disease symptoms in sedentary adults with schizophrenia. Ages 21-64. Location in La Jolla, CA.

• Ziprasidone for Improving Insulin Sensitivity in People With Schizophrenia Who Are at Risk for Diabetes.
  Interventional study. This study will evaluate the effectiveness of ziprasidone treatment versus treatment with a standard atypical antipsychotic drug in improving insulin sensitivity and reducing excess abdominal fat storage in people with schizophrenia who are at risk for diabetes. Ages 18-65. Location in San Diego, CA.

• Cognitive Behavioral Social Skills Training for Improving Social Functioning in People With Schizophrenia.
  Interventional study. This study will evaluate the effectiveness of cognitive behavioral social skills training versus supportive contact in improving social functioning in people with schizophrenia. Ages 18 and over. Location in San Diego, CA.

• Psychosocial Therapy and Risperidone Treatment in Work Performance in Recent-Onset Schizophrenia.
  Interventional study. This study will determine the effectiveness of various combinations of psychosocial therapy and risperidone treatment in improving work or school performance in people with first-episode schizophrenia. Ages 18-45. Location in Los Angeles, CA.

• Oral Versus Injectable Risperidone for Treating First-Episode Schizophrenia.
  Interventional study. This study will determine the effectiveness of oral risperidone versus long-acting injectable risperidone in treating people with first-episode schizophrenia. Ages 18-45. Location in Los Angeles, CA.

• Preventing Relapse in Schizophrenia: Oral Antipsychotics Compared To Injectables: Evaluating Efficacy.
  Interventional study. This study is designed to find out whether taking antipsychotic medication once every two weeks by injection compared to taking daily oral medication will help people with schizophrenia maintain better control of their symptoms. Ages 18-65. Locations in Augusta, GA; Iowa City, IA; Boston, MA; Fall River, MA; Omaha, NE; Albuquerque, NM; Glen Oaks, NY.

• Safety and Effectiveness of D-Serine in Schizophrenia.
  Interventional study. This study will determine whether increasing D-serine within the body will improve negative symptoms and cognitive impairments in people with schizophrenia. Ages 18-60. Locations in New Haven, CT; Glen Oaks, NY; Orangeburg, NY.

• Comparison of Aripiprazole and Risperidone for the Treatment of People With First-Episode Psychosis.
  Interventional study. This study will evaluate the effectiveness of aripiprazole versus risperidone in treating people with first-episode schizophrenia. Ages 15-40. Locations in Newark, NJ; Bronx, NY; Brooklyn, NY; Glen Oaks, NY; Jamaica, NY; Manhasset, NY.

• Effectiveness of Targeted Cognitive Training for Neurological Deficits in People With Schizophrenia.
  Interventional study. This study will determine the effectiveness of reward-intensive, computer-based targeted cognitive training in improving neurocognitive deficits in people with schizophrenia. Ages 18-60. Location in San Francisco, CA.

• Effectiveness of Transcranial Magnetic Stimulation for Reducing "Voices" in People With Schizophrenia.
  Interventional study. This study will evaluate the effectiveness of MRI-guided transcranial magnetic stimulation in improving the "voices" and other symptoms experienced by people with schizophrenia. Ages 18-55. Location in New Haven, CT.

• Graduated Recovery Intervention Program for Enhancing Treatment for First-Episode Psychosis.
  Interventional study. This study will determine the effectiveness of the Graduated Recovery Intervention Program, a manual-based individual therapy program, in enhancing the clinical benefit of routine treatment for individuals recovering from their first episodes of psychosis. Ages 18 and over. Location in Chapel Hill, NC.

• Identifying Factors That Affect Basic Symptoms of Psychosis.
  Evaluation study. This study will gather information on the natural history of the basic symptoms of psychosis to identify factors that may affect the improvement or persistence of the symptoms. Ages 12-35. Locations in New Haven, CT; Chapel Hill, NC; Toronto, ON.

• Investigation of the Drug Dimethoxbenzylidene Anabaseine in Treating Schizophrenia Patients.
  Interventional study. This study will determine the effectiveness of a drug, dimethoxbenzylidene anabaseine, in producing beneficial effects similar to that of nicotine in individuals with schizophrenia. Ages 18-60. Location in Denver, CO.

• The Genetic Basis of Inherited Neurologic Deficits in People With Schizophrenia.
  Evaluation study. This is a study of the genetic basis of brain dysfunction in people with schizophrenia. Ages 18 and over. Locations in Los Angeles, CA; San Diego, CA; Denver, CO; Boston, MA; New York, NY; Philadelphia, PA; Seattle, WA.

• Side Effects of Newer Antipsychotics in Older Adults.
  Interventional study. This study will compare four atypical antipsychotic medications in terms of the risk of specific side effects each of them presents in middle-aged and elderly individuals. Ages 45 and over. Location in San Diego, CA.

• Evaluating the Effectiveness of a Weight Loss Program for Overweight and Obese People With Schizophrenia.
  Interventional study. This study will evaluate the effectiveness of a behavioral weight loss program for overweight and obese people with schizophrenia. Ages 14-60. Location in Pittsburgh, PA.

• D-Serine for Enhancing Cognitive Retraining for the Treatment of Schizophrenia.
  Interventional study. This study will examine the effectiveness of D-serine in increasing and sustaining the benefits of cognitive retraining in people with schizophrenia. Ages 18-65. Location in Bangalore, India.

• Determining Metabolic Effects of Valproate and Antipsychotic Therapy.
  Interventional study. This study will determine the metabolic processes responsible for high levels of blood glucose, metabolism disorders, and weight gain in people with schizophrenia who have been treated with antipsychotic medications in combination with valproate. Ages 18-60. Location in St. Louis, MO.

• Effectiveness of Pimozide in Augmenting the Effects of Clozapine in the Treatment of Schizophrenia.
  Interventional study. This study will assess the effectiveness of pimozide in enhancing the effects of clozapine in the treatment of schizophrenia. Ages 18-65. Locations in New York, NY; W. Brentwood, NY.

• Addition of Ondansetron to Ongoing Antipsychotic Treatment for Schizophrenia.
  Interventional study. This study will examine the effects of ondansetron on auditory nerve activity in people with schizophrenia who are being treated with new antipsychotics. Ages 18-55. Location in Denver, CO.

• Treatment Response to Rehabilitation in Patients With Schizophrenia.
  Evaluation study. This study will examine the ways in which schizophrenia-related symptoms affect response to a rehabilitation program for people with schizophrenia. Ages 18 and over. Location in Hartford, CT.

• Effects of Modafinil on Brain Function in Patients With Schizophrenia.
  Interventional study. This study will evaluate whether modafinil improves cognition in patients with schizophrenia and healthy volunteers. Ages 18-60. Location in Bethesda, MD.

• Risperidone Treatment in Schizophrenia Patients Who Are Currently Taking Clozapine.
  Interventional study. This study will determine whether adding the drug risperidone (Risperdal®) is more effective than placebo in treating schizophrenic patients who are taking the drug clozapine. Ages 18-65. Location in Baltimore, MD.

• Treating Drug-Resistant Childhood Schizophrenia.
  Interventional study. This study will compare clozapine and olanzapine (Zyprexa®) for the treatment of children and adolescents who have failed standard antipsychotic treatment for schizophrenia. Ages 10-18. Locations in Bronx, NY; Dix Hills, NY; Glen Oaks, NY.

• Switching Medication to Treat Schizophrenia.
  Interventional study. This study will evaluate the effectiveness of switching medications in decreasing schizophrenia symptoms in individuals who are currently taking an antipsychotic medication for the treatment of schizophrenia. Ages 18 and over. Locations in Hartford, CT; New Haven, CT; Boca Raton, FL; Miami, FL; Fall River, MA; Worcester, MA; Glen Burnie, MD; Minneapolis, MN; St. Louis, MO; Butner, NC; Bronx, NY; Cincinnati, OH; Philadelphia, PA; Dallas, TX; San Antonio, TX; Tacoma, WA.

• Clinical Trial of Tolcapone for Cognition in Schizophrenia.
  Interventional study. This study will evaluate whether Atomoxetine improves cognition in healthy volunteers as well as patients with schizophrenia. Ages 18-60. Location in Bethesda, MD.

• Molecular Genetics of Schizophrenia.
  Evaluation study. This study will create a DNA collection with blood samples from families with at least two siblings who have schizophrenia symptoms. Ages 18 and over. Locations in Brisbane, Australia; Irvine, CA; Denver, CO; Atlanta, GA; Iowa City, IA; Evanston, IL; New Orleans, LA; St. Louis, MO; New York, NY; Philadelphia, PA.

• Magnetic Resonance Imaging (MRI) of Neuropsychiatric Patients and Healthy Volunteers.
  Evaluation study. The purpose of this study is to use brain imaging technology to compare differences in brain structure, chemistry, and functioning in individuals with brain and mental disorders compared to healthy volunteers. Ages 18 and over. Location in Bethesda, MD.

• Evaluation of the Genetics of Bipolar Disorder.
  Evaluation study. This study looks to identify genes that may affect a person's chances of developing bipolar disorder (BP) and related conditions. Ages 18 and over. Locations in La Jolla, CA; Orange, CA; Washington, DC; Iowa City, IA; Chicago, IL; Indianapolis, IN; Louisville, KY; Baltimore, MD; Detroit, MI; St. Louis, MO; Stonybrook, NY; Philadelphia, PA.

• Evaluating Genetic Risk Factors for Childhood-Onset Schizophrenia.
  Evaluation study. A study of children and adolescents (current N=48) with very early onset by age 12 (COS) of DSM-III-R defined schizophrenia with (97-M-0126) is examining the clinical, neurobiological, early neurodevelopmental, genetic, and clinical drug response characteristics of these cases. Ages 6-70. Location in Bethesda, MD.

• Inpatient Evaluation of Adults With Schizophrenia.
  Evaluation study. The purpose of this study is to understand the biologic basis of schizophrenia and to determine which symptoms are related to the illness itself and which are related to medications used to treat the illness. Ages 18 and over. Location in Bethesda, MD.

• Studies of Frontal Lobe Brain Functioning in Schizophrenia.
  Evaluation study. The purpose of this study is to use brain imaging technology to investigate the role of the frontal lobe of the brain in the thinking of individuals with schizophrenia and other neuropsychiatric disorders and healthy volunteers. Ages 18-90. Location in Bethesda, MD.

• Brain Tissue Collection for Neuropathological Studies.
  Evaluation study. The purpose of this study is to collect and study the brain tissue of deceased individuals to learn more about the nervous system and mental disorders. Locations in Washington, DC; Bethesda, MD; Fairfax, VA.

• Magnetic Resonance Imaging (MRI) of Neuropsychiatric Patients and Healthy Volunteers.
  Evaluation study. The purpose of this study is to use brain imaging technology to compare differences in brain structure, chemistry, and functioning in individuals with brain and mental disorders compared to healthy volunteers. Ages 18 and over. Location in Bethesda, MD.

• Genetic Study of Schizophrenia.
  Evaluation study. This large ongoing study at NIMH investigates the neurobiology of schizophrenia by identifying susceptibility genes, evaluating their impact on brain function to better understand how to treat and prevent this illness. Ages 18 and over. Location in Bethesda, MD.

• Electrophysiology and Blood Flow in Patients With Schizophrenia and Their Siblings.
  Evaluation study. This study will explore how the brain works during memory testing in an effort to understand why some patients with schizophrenia have memory difficulties. Ages 18-55. Location in Bethesda, MD.

Source: National Institute of Mental Health

Dr. Jeffrey Speller
Dr. Tanya Korkosz
Psychopharmacology Associates of New England
www.psychopharmassociates.com

The best patient guide on clinical trials for Post-Traumatic Stress Disorder (PTSD)

Post-Traumatic Stress Disorder (PTSD)

Featured Studies

Featured studies include only those currently recruiting participants. They are listed according to the date they were added to the ClinicalTrials.gov registry, with the most recent studies appearing first.

• Effectiveness of Three Different Psychotherapies for Chronic Post-Traumatic Stress Disorder.
  Interventional study. This study will examine whether interpersonal psychotherapy is as effective in treating post-traumatic stress disorder as the established therapies of prolonged exposure and relaxation. Ages 18-65. Location in New York, NY.

• Effectiveness of a Web-Based Intervention for Guardians of Children Whose One Parent Has Murdered the Other.
  Interventional study. This study will determine whether a specialized Web site geared for the guardians of children whose one parent has murdered the other can increase guardian capabilities, reduce guardian stress, and improve child behavior and mental health. Ages 18 and over. Location in Charlottesville, VA.

• Effectiveness of Cognitive Behavioral Couples Therapy for Post-Traumatic Stress Disorder.
  Interventional study. This study will evaluate the effectiveness of cognitive behavioral couples therapy designed for post-traumatic stress disorder in reducing symptoms of post-traumatic stress disorder and in improving relationship functioning. Ages 18-65. Location in Boston, MA.

• Effectiveness of Propranolol For Treating People With Post-Traumatic Stress Disorder.
  Interventional study. This study will evaluate the effectiveness of propranolol in reducing symptoms of distress in people with post-traumatic stress disorder. Ages 18-50. Location in New York, NY.

• Effectiveness of an Adaptive Treatment Model for At-Risk Family Caregivers.
  Interventional study. This study will develop and evaluate the effectiveness of an adaptive treatment model for reducing the stress of, and burden on, family members caring for a person with dementia. Ages 18 and over. Location in Cleveland, OH.

• Effectiveness of Trauma-Focused Cognitive Behavioral Therapy in Treating Children With Post-Traumatic Stress Disorder.
  Interventional study. This study will compare the effectiveness of trauma-focused cognitive behavioral therapy versus standard care in treating children with post-traumatic stress disorder. Ages 8-18. Location in New York, NY.

• Cognitive Behavioral Therapy for Treating Recently Abused Women With Post-Traumatic Stress Disorder.
  Interventional study. This study will evaluate the effectiveness of a brief cognitive behavioral treatment, Helping to Overcome PTSD through Empowerment, in treating abused women with post-traumatic stress disorder who are living in shelters. Ages 18 and over. Location in Akron, OH.

• Evaluating the Effects of Stress in Pregnancy.
  Evaluation study. This study will evaluate pregnant women with a past or current diagnosis of depression or anxiety to gain a better understanding of how these disorders can affect an infant's development, both during and after pregnancy. Ages 18-45. Location in Atlanta, GA.

• Cognitive Behavioral Treatment for Post-Traumatic Stress Disorder in People With Additional Serious Mental Illnesses.
  Interventional study. This study will evaluate the effectiveness of tailored cognitive behavioral therapy in treating post-traumatic stress disorder in people with additional mental illnesses. Ages 18 and over. Locations in New Brunswick, NJ; Newark, NJ.

• Comparing Behavioral Therapies for Treating Adolescents With Post-Traumatic Stress Disorder Related to Sexual Abuse.
  Interventional study. This study will evaluate the comparative effectiveness of prolonged exposure therapy and supportive counseling in treating adolescents with post-traumatic stress disorder related to childhood sexual abuse or assault. Ages 13-18. Location in Philadelphia, PA.

• Development of Magnetic Resonance Imaging Techniques for Studying Mood and Anxiety Disorders.
  Evaluation study. This study is intended to help develop new MRI imaging techniques for studying mood and anxiety disorders. Ages 18-50. Location in Bethesda, MD.

• Cognitive Behavioral Therapy Versus Sertraline in the Treatment of Post-Traumatic Stress Disorder.
  Interventional study. This study will evaluate which parts of the brain are affected by treatment with behavioral therapy versus medication therapy in people with post-traumatic stress disorder. Ages 18-55. Location in New York, NY.

• Substance P Antagonist in the Treatment of Posttraumatic Stress Disorder.
  Interventional study. This study, conducted at the NIH and the Mount Sinai School of Medicine, will examine the effectiveness of a substance P or NK1 antagonist study drug known as GR205171 in treating the symptoms of posttraumatic stress disorder (PTSD). Ages 18-65. Locations in Bethesda, MD; New York, NY.

• Effectiveness of Virtual Reality Exposure Therapy and D-Cycloserine to Treat Iraq War Veterans With Post-Traumatic Stress Disorder.
  Interventional study. This study will determine whether a combination of virtual reality exposure therapy and D-cycloserine will reduce post-traumatic stress disorder symptoms in Iraq war veterans. Ages 21-65. Location in Atlanta, GA.

• Cognitive Behavioral Therapy for Post-Traumatic Stress Disorder in Homeless Women.
  Interventional study. This study will determine the effectiveness of cognitive behavioral therapy in treating post-traumatic stress disorder in homeless women. Ages 18 and over. Location in , .

• Patient-Centered Collaborative Care for Preventing Post-Traumatic Stress Disorder After Traumatic Injury.
  Interventional study. This study will evaluate the effectiveness of patient-centered collaborative care that combines behavioral therapy and drug therapy as compared to usual care in reducing symptoms of post-traumatic stress disorder in people who have survived a traumatic injury. Ages 18 and over. Location in Seattle, WA.

• Effectiveness of an NK1 Antagonist in Decreasing Symptoms of Post-Traumatic Stress Disorder.
  Interventional study. This study will evaluate the effectiveness of the Nk1 antagonist, GR205171, as compared to placebo, in improving overall PTSD symptoms. Ages 18-65. Location in New York, NY.

• Prazosin for Treating Noncombat Trauma Post-Traumatic Stress Disorder.
  Interventional study. This study will evaluate the effectiveness of prazosin in treating post-traumatic stress disorder caused by noncombat trauma in individuals taking selective serotonin reuptake inhibitors. Ages 18 and over. Location in Seattle, WA.

• Treating Post Traumatic Stress Disorder in Children Exposed to Domestic Violence.
  Interventional study. This study will determine whether trauma-focused cognitive behavioral therapy (TF-CBT) is more effective than child-centered therapy (CCT) in reducing post traumatic stress disorder (PTSD) in children exposed to domestic violence (DV). Ages 7-14. Location in Pittsburgh, PA.

• Effect of Propranolol on Preventing Post-Traumatic Stress Disorder.
  Interventional study. This study will assess the effectiveness of taking propranolol soon after a traumatizing incident in reducing the incidence and severity of post-traumatic stress disorder in acutely traumatized individuals. Ages 18-55. Location in Boston, MA.

• Comparison of Two Treatments for Post-Traumatic Stress Disorder.
  Interventional study. This study will compare the short- and long-term effectiveness of two different treatments for people with post-traumatic stress disorder. Ages 18-65. Locations in Cleveland, OH; Seattle, WA.

• Psychobiological Mechanisms of Resilience to Trauma.
  Evaluation study. This study will evaluate brain changes and psychological characteristics of people who are resilient to trauma. Ages 18 and over. Locations in Washington, DC; Bethesda, MD.

• Brain Function in Mentally Ill Adolescents.
  Evaluation study. The purpose of this study is to use brain imaging technology to examine the brain activity of adolescents with post-traumatic stress disorder (PTSD) and/or major depressive disorder (MDD) before and after treatment. Ages 7-18. Locations in Newark, DE; Bethesda, MD.

Source: National Institute of Mental Health

Dr. Jeffrey Speller
Dr. Tanya Korkosz
Psychopharmacology Associates of New England
www.psychopharmassociates.com

The best patient guide on clinical trials for Panic Disorder

Panic Disorder

Featured Studies

Featured studies include only those currently recruiting participants. They are listed according to the date they were added to the ClinicalTrials.gov registry, with the most recent studies appearing first.

• Effectiveness of Intensive Cognitive Behavioral Therapy in Treating Adolescent Panic Disorder and Agoraphobia.
  Interventional study. This study will evaluate the effectiveness of intensive cognitive behavioral therapy in treating adolescents with panic disorder with agoraphobia. Ages 12-17. Location in Boston, MA.

• Evaluating the Relationship Between Tobacco Use, Anxiety Sensitivity, and Panic in Adolescents.
  Evaluation study. This study will determine whether there is a relationship between tobacco use and a heightened response to panic-producing events among adolescents. Ages 12-17. Location in Fayetteville, AR.

• Evaluating the Effects of Stress in Pregnancy.
  Evaluation study. This study will evaluate pregnant women with a past or current diagnosis of depression or anxiety to gain a better understanding of how these disorders can affect an infant's development, both during and after pregnancy. Ages 18-45. Location in Atlanta, GA.

• Development of Magnetic Resonance Imaging Techniques for Studying Mood and Anxiety Disorders.
  Evaluation study. This study is intended to help develop new MRI imaging techniques for studying mood and anxiety disorders. Ages 18-50. Location in Bethesda, MD.

• Comparison of Psychotherapy Programs to Treat Panic Disorder.
  Interventional study. This study will determine the relative effectiveness of three psychotherapies in treating people with a panic disorder. Ages 18-70. Locations in New York, NY; Philadelphia, PA.

• Breathing Regulation Training for Individuals With Panic Disorder.
  Interventional study. This study will compare two different breathing regulation techniques to determine which is more effective in reducing the rate of panic attacks in people with panic disorder. Ages 18-60. Location in Palo Alto, CA.

• Neurobiological Mechanisms in Panic Disorder.
  Evaluation study. This study will examine brain and noradrenaline function in panic disorder. Ages 18-60. Location in Bethesda, MD.

• Genetic Causes of Panic Disorder.
  Evaluation study. This study will try to identify genes that increase the risk of developing panic disorder-an anxiety disorder characterized by recurrent unexpected panic attacks-and that contribute to the abnormalities associated with it. Ages 18-60. Locations in Washington, DC; Bethesda, MD.

Source: National Institute of Mental Health

Dr. Jeffrey Speller
Dr. Tanya Korkosz
Psychopharmacology Associates of New England
www.psychopharmassociates.com

The best patient guide on clinical trials for Obsessive-Compulsive Disorder

Obsessive-Compulsive Disorder (OCD)

Featured Studies

Featured studies include only those currently recruiting participants. They are listed according to the date they were added to the ClinicalTrials.gov registry, with the most recent studies appearing first.

• Cognitive Behavioral Therapy for Pediatric Obsessive-Compulsive Disorder.
  Interventional study. This study will examine the way cognitive behavioral therapy changes the structure of the brain in patients with obsessive-compulsive disorder and will thereby determine what makes cognitive behavioral therapy an effective treatment. Ages 6-18. Location in Los Angeles, CA.

• Effectiveness of Deep Brain Stimulation for Treating People With Treatment Resistant Obsessive-Compulsive Disorder.
  Interventional study. This study will evaluate the safety and effectiveness of deep brain stimulation in treating people with severe and otherwise treatment-resistant obsessive-compulsive disorder. Ages 18-65. Locations in Gainesville, FL; Boston, MA; Bethesda, MD; Cleveland, OH; Providence, RI.

• Comparing the Effectiveness of Two Family-Based Therapies in Treating Young Children With Obsessive-Compulsive Disorder.
  Interventional study. This study will compare the effectiveness of family-based cognitive behavioral therapy to family-based relaxation therapy in treating young children with obsessive-compulsive disorder. Ages 5-8. Locations in Durham, NC; Philadelphia, PA; Providence, RI.

• Evaluating the Effects of Stress in Pregnancy.
  Evaluation study. This study will evaluate pregnant women with a past or current diagnosis of depression or anxiety to gain a better understanding of how these disorders can affect an infant's development, both during and after pregnancy. Ages 18-45. Location in Atlanta, GA.

• Pharmacogenomics of Antidepressant Response in Children and Adolescents.
  Evaluation study. This study will identify variations in genes that may be involved in the development of suicidal events or certain behaviors in youth who are exposed to antidepressant medications. Ages 7-17. Location in Durham, NC.

• Evaluating Parenting Styles and Child Temperament Associated With Child Anxiety Disorders.
  Evaluation study. This study will look at similarities and differences in family processes and child temperament among children with and without symptoms of anxiety disorders. Ages 8-12. Location in Providence, RI.

• Antidepressant Safety in Kids Study.
  Evaluation study. This study will evaluate the risks and benefits of treatment with a selective serotonin reuptake inhibitor or serotonin-norepinephrine reuptake inhibitor in children and adolescents with a pre-specified anxiety disorder, depressive disorder, eating disorder, or obsessive-compulsive disorder. Ages 7-17. Location in Durham, NC.

• Risperidone or Cognitive-Behavioral Therapy for Improving Medication Treatment for Obsessive-Compulsive Disorder.
  Interventional study. This study will compare the short- and long-term effectiveness of two common therapies in improving serotonin reuptake inhibitor treatment in people with obsessive-compulsive disorder. Ages 18-70. Locations in New York, NY; Philadelphia, PA.

• Cognitive Behavioral Therapy Plus Motivational Interviewing for Treatment of Obsessive-Compulsive Disorder.
  Interventional study. This study will determine the effectiveness of adding motivational interviewing to cognitive behavioral therapy, consisting of exposure and ritual prevention, in improving treatment outcomes in people with obsessive-compulsive disorder. Ages 18-70. Location in New York, NY.

• Stepped Care for Treating Obsessive-Compulsive Disorder.
  Interventional study. This study will determine the effectiveness and cost-effectiveness of a stepped-care treatment program for people with obsessive-compulsive disorder. Ages 18-69. Location in Hartford, CT.

• Riluzole to Treat Child and Adolescent Obsessive-Compulsive Disorder With or Without Autism Spectrum Disorders.
  Interventional study. This study will examine the effectiveness of riluzole for treating Obsessive-Compulsive Disorder in Youth, Including those with Autism Spectrum Disorders. Ages 7-17. Location in Bethesda, MD.

• Treatment of Obsessive Compulsive Disorder in Children.
  Interventional study. This study will determine whether cognitive behavioral therapy delivered by either psychologists or psychiatrists can improve the effectiveness of serotonin reuptake inhibitor treatment in children with obsessive compulsive disorder. Ages 7-17. Locations in Durham, NC; Philadelphia, PA; Providence, RI.

• Genetics of Obsessive-Compulsive Disorder.
  Evaluation study. The purpose of this study is to identify genes that affect susceptibility to obsessive-compulsive disorder (OCD). Ages 18 and over. Locations in Newcastle, Australia; New Haven, CT; Tallahassee, FL; Boston, MA; Baltimore, MD; Durham, NC; Providence, RI; Nashville, TN.

Source: National Institute of Mental Health

Dr. Jeffrey Speller
Dr. Tanya Korkosz
Psychopharmacology Associates of New England
www.psychopharmassociates.com